



Microfracture vs Microfracture Plus BioCartilage® Matrix in Knee Lesions

Purpose

To report the clinical outcomes of pain, function, and quality of life for patients who underwent cartilage treatment comparing Microfracture alone with Microfracture plus Arthrex BioCartilage Extracellular Matrix.

Methods


The inclusion criteria for this analysis were patients enrolled in the Surgical Outcomes System™ global registry who underwent cartilage treatment, either microfracture alone or Microfracture with Arthrex BioCartilage Extracellular Matrix. Standard patient reported outcome questionnaires for VAS, KOOS ADL function and, SANE Knee were administered at standard time points post treatment. Results were reported from presurgery out to 5 years postsurgery. The number of patients included is shown to the right.

Time Point	# of Compliant MFX Patients/Total # of MFX Patients	# of Compliant MFX + Biocart Patients/Total # MFX + Biocart Patients
Presurgery	377/534	15/42
6 months	320/495	23/40
1 year	256/446	22/40
2 years	169/336	14/37


Trend Conclusion

Based on these results, Microfracture cartilage treatment augmented with Arthrex BioCartilage extracellular matrix trend toward better outcomes than the scores of patients who underwent Microfracture cartilage treatment alone. However, no claims can be made on the potential of these results without further statistical analysis. More patients and more scores are needed to evaluate long-term success.


Results



VAS



KOOS ADL



KOOS WOMAC Function

Time Point	Microfracture Avg \pm STD VAS	Microfracture + BioCart Avg \pm STD VAS
Presurgery	3.9 \pm 2.5	4.0 \pm 2.7
6 months	2.1 \pm 2.2	1.5 \pm 1.6
1 year	2.0 \pm 2.1	1.0 \pm 1.4
2 years	1.8 \pm 2.1	1.6 \pm 2.1

Time Point	Microfracture Avg \pm STD KOOS ADL	Microfracture + BioCart Avg \pm STD KOOS ADL
Presurgery	65.0 \pm 20.6	70.0 \pm 23.7
6 months	82.8 \pm 17.3	87.9 \pm 12.2
1 year	85.2 \pm 16.7	94.7 \pm 6.7
2 years	84.3 \pm 18.6	92.9 \pm 9.3

Time Point	Microfracture Avg \pm STD KOOS WOMAC Function	Microfracture + BioCart Avg \pm STD KOOS WOMAC Function
Presurgery	65.0 \pm 20.6	70.0 \pm 23.7
6 months	82.9 \pm 17.2	87.9 \pm 12.2
1 year	85.2 \pm 16.7	94.7 \pm 6.7
2 years	84.3 \pm 18.6	92.9 \pm 9.3